These studies demonstrate that NR4A1 is a target for NR4A1 antagonists in RCC cells; this leads to inhibition of several NR4A1-regulated pro-oncogenic pathways (Fig 1A) including mTOR and these results are comparable to those observed in pancreatic, lung and colon cancer cells and tumors [14–17]. Here, MTOR is linked to renal cell adenocarcinoma.